






(86) Date de dépôt PCT/PCT Filing Date: 2015/04/03
(87) Date publication PCT/PCT Publication Date: 2015/10/08
(45) Date de délivrance/Issue Date: 2022/07/26
(85) Entrée phase nationale/National Entry: 2016/09/29
(86) N° demande PCT/PCT Application No.: US 2015/024216
(87) N° publication PCT/PCT Publication No.: 2015/153955
(30) Priorité/Priority: 2014/04/04 (US61/975,089)

(51) Cl.Int./Int.Cl. *C07D 487/04* (2006.01),
A61K 31/519 (2006.01), *A61P 35/00* (2006.01)
(72) Inventeur/Inventor:
GANGJEE, ALEEM, US
(73) Propriétaire/Owner:
DUQUESNE UNIVERSITY OF THE HOLY SPIRIT, US
(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : COMPOSES DE PYRIMIDINE BICYCLIQUES SUBSTITUES PAR DE LA TUBULINE ET INHIBITION DE
MULTIPLES RECEPTEURS
(54) Title: SUBSTITUTED BICYCLIC PYRIMIDINE COMPOUNDS WITH TUBULIN AND MULTIPLE RECEPTOR
INHIBITION



R
3 H
4 CH₃



R
2 H
5 CH₃

(57) **Abrégé/Abstract:**

This invention provides substituted bicyclic pyrimidine compounds and pharmaceutically acceptable salts, hydrates, and solvates of the compounds, each having tubulin and multiple receptor inhibition properties. Methods of treating a patient diagnosed with cancer is disclosed comprising administering to the patient a therapeutically effective amount of the substituted bicyclic pyrimidine compounds and pharmaceutically acceptable salts, hydrates, and solvates of the compounds, for treating cancer.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(10) International Publication Number
WO 2015/153955 A1(43) International Publication Date
8 October 2015 (08.10.2015)

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 35/00 (2006.01)
C07D 487/04 (2006.01)

(21) International Application Number:

PCT/US2015/024216

(22) International Filing Date:

3 April 2015 (03.04.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/975,089 4 April 2014 (04.04.2014) US

(71) Applicant: DUQUESNE UNIVERSITY OF THE
HOLY SPIRIT [US/US]; 309 Administration Building,
600 Forbes Avenue, Pittsburgh, Pennsylvania 15282 (US).(72) Inventor: GANGJEE, Aleem; 3855 Oakbrook Court, Al-
lison Park, Pennsylvania 15101 (US).(74) Agent: COCHENOUR, Craig G.; Buchanan Ingersoll &
Rooney PC, One Oxford Centre, 301 Grant Street, 20th
Floor, Pittsburgh, Pennsylvania 15219 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))


(54) Title: SUBSTITUTED BICYCLIC PYRIMIDINE COMPOUNDS WITH TUBULIN AND MULTIPLE RECEPTOR INHIBI-
TION

Figure 1

(57) Abstract: This invention provides substituted bicyclic pyrimidine com-
pounds and pharmaceutically acceptable salts, hydrates, and solvates of the
compounds, each having tubulin and multiple receptor inhibition properties.
Methods of treating a patient diagnosed with cancer is disclosed comprising
administering to the patient a therapeutically effective amount of the substi-
tuted bicyclic pyrimidine compounds and pharmaceutically acceptable salts,
hydrates, and solvates of the compounds, for treating cancer.

Also identified as	Compound number, Figure 1
RP/AG/159- 306	2
RP/AG/159- 313	3
RP/AG/159- 321	4
RP/AG/159- 341	5

SUBSTITUTED BICYCLIC PYRIMIDINE COMPOUNDS WITH TUBULIN AND MULTIPLE RECEPTOR INHIBITION

FIELD OF THE INVENTION

This invention provides for the design and preclinical evaluation of substituted bicyclic pyrimidine compounds (as single agents) having tubulin and multiple receptor tyrosine kinase inhibition.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The substituted bicyclic pyrimidine compounds of the present invention are single agents that have both cytotoxic and antiangiogenic effects. The antiangiogenic effect is mediated via inhibition of vascular endothelial growth factor -2 (VEGFR2). The cytotoxic effect is mediated by tubulin inhibition. The compounds, pharmaceutical compositions comprising the compounds, or their salts, solvates, and hydrates thereof, overcome two clinically important tumor resistance mechanisms that limit the activity of microtubule targeting agents: expression of P-glycoprotein and β III tubulin.


2. Description of the Background Art

Agents that interfere with microtubules are important antitumor agents. Tumor angiogenic mechanisms that are vital for tumor growth and metastasis are targeted by antiangiogenic agents. Antiangiogenic agents are usually not tumoricidal but are mainly cytostatic. Combination chemotherapy with antiangiogenic and cytotoxic agents have shown significant promise and several studies with such combinations are in progress in the clinic.

SUMMARY OF THE INVENTION


This invention provides substituted bicyclic pyrimidine compounds and pharmaceutical composition comprising these compounds and salts, solvates and hydrates of these compounds. The compounds of this invention may act as single agents with both antiangiogenic and cytotoxic activities. The compounds of this invention have the advantages of circumventing the pharmacokinetic problems associated with delivery of multiple agents, of avoiding drug-drug interactions, of alleviating toxicity, and of delaying or preventing tumor cell resistance.

The present invention provides a compound comprising the following formula:



wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated. Another embodiment of this invention provides a pharmaceutical composition comprising this compound and pharmaceutically acceptable salts, hydrates, and solvates thereof.

Another embodiment of this invention provides a compound comprising the following formula:



wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated. Another embodiment of this invention provides a pharmaceutical composition comprising this compound and pharmaceutically acceptable salts, hydrates, and solvates thereof.

In yet another embodiment of this invention, the following compounds are provided consisting of the group selected of 7-Benzyl-2-methyl-3*H*-pyrrolo[3,2-*d*]pyrimidin-4(5*H*)-one, 7-Benzyl-4-chloro-2-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, 7-Benzyl-4-chloro-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, 1-(7-Benzyl-2-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, 7-Benzyl-*N*-(4-methoxyphenyl)-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine, 7-Benzyl-*N*-(4-methoxyphenyl)-*N*,2,5-trimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine, and 1-(7-Benzyl-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, and pharmaceutical compositions of these compounds comprising pharmaceutically acceptable salts, hydrates, and solvates thereof.

Another embodiment of this invention provides a method of treating a patient diagnosed with cancer comprising administering to the patient a therapeutically effective amount of the compounds described herein, or optionally pharmaceutical compositions comprising a therapeutically effective amount of these compounds as described herein and pharmaceutically acceptable salts, hydrates, and solvates thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows compounds that are preferred embodiments of this invention.

Figure 2 shows the effect of the HCl salt form of Compound 4 of this invention (chemical structure of Compound 4 shown in Figure 1) upon triple negative mouse tumors.

Figure 3 shows the effect of the HCl salt form of Compound 4 of this invention (chemical structure of Compound 4 shown in Figure 1) upon animal weight.

Figure 4 shows the effect of the HCl salt form of Compound 4 of this invention (chemical structure of Compound 4 shown in Figure 1) on tumor weight.

Figure 5 shows the effect of the HCl form of Compound 4 of this invention (chemical structure of Compound 4 shown in Figure 1) upon lung micrometastases and macrometastases.


DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein, the term "patient" means members of the animal kingdom, including, but not limited to, human beings.

As used herein, the term "having cancer" means that the patient has been diagnosed with cancer. As used herein, the term "therapeutically effective amount" refers to that amount of any of the present compounds, or a pharmaceutical composition comprising any one or more of the compounds, or pharmaceutically acceptable salts, hydrates, or solvates thereof, required to bring about a desired effect in a patient. The desired effect will vary depending on the illness being treated. For example, the desired effect may be reducing tumor size, destroying cancerous cells, and/or preventing metastasis, any one of which may be the desired therapeutic response. On its most basic level, a therapeutically effective amount is that amount needed to inhibit the mitosis of a cancerous cell or to facilitate the reversal of multidrug resistance, particularly, for example due to P-glycoprotein, (i.e. an effective mitotic inhibitory amount) or β III tubulin. Any amount


of mitotic inhibition or reversal of multidrug resistance will yield a benefit to a patient and is therefore within the scope of the invention.

The present invention provides a compound comprising the following formula:



wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated. Another embodiment of this invention provides a pharmaceutical composition comprising this compound and pharmaceutically acceptable salts, hydrates, and solvates thereof.


Another embodiment of this invention provides a compound comprising the following formula:



wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated. Another embodiment of this invention provides a pharmaceutical composition comprising this compound and pharmaceutically acceptable salts, hydrates, and solvates thereof.


In yet another embodiment of this invention, the following compounds are provided consisting of the group selected of 7-Benzyl-2-methyl-3*H*-pyrrolo[3,2-*d*]pyrimidin-4(5*H*)-one, 7-Benzyl-4-chloro-2-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, 7-Benzyl-4-chloro-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, 1-(7-Benzyl-2-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, 7-Benzyl-*N*-(4-methoxyphenyl)-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine, 7-Benzyl-*N*-(4-methoxyphenyl)-*N*,2,5-trimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine, and 1-(7-Benzyl-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, and pharmaceutical compositions of these compounds comprising pharmaceutically acceptable salts, hydrates, and solvates thereof.

Another embodiment of this invention provides a method of treating a patient diagnosed with cancer comprising administering to the patient a therapeutically effective amount of a compound having the formula:



wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated, or optionally administering a therapeutically effective amount of said compound comprising pharmaceutically acceptable salts, hydrates, and solvates thereof, for treating the patient diagnosed with cancer.

Another embodiment of this invention provides a method of treating a patient diagnosed with cancer comprising administering to the patient a therapeutically effective amount of a compound having the formula:



wherein R is selected from the group consisting of H and a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated, or optionally administering a therapeutically effective amount of said compound comprising pharmaceutically acceptable salts, hydrates, and solvates thereof, for treating the patient diagnosed with cancer.

Another embodiment of this invention provides a method of treating a patient diagnosed with cancer comprising administering to the patient a therapeutically effective amount of a compound selected from the group of 7-Benzyl-2-methyl-3*H*-pyrrolo[3,2-*d*]pyrimidin-4(5*H*)-one, 7-Benzyl-4-chloro-2-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, 7-Benzyl-4-chloro-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, 1-(7-Benzyl-2-methyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, 7-Benzyl-*N*-(4-methoxyphenyl)-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine, 7-Benzyl-*N*-(4-methoxyphenyl)-*N*,2,5-trimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine, and 1-(7-Benzyl-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, or optionally administering a therapeutically

effective amount of said compound comprising pharmaceutically acceptable salts, hydrates, and solvates thereof, for treating the patient diagnosed with cancer.

This invention provides single agents, for example but not limited to, Compounds 1-5 of Figure 1 that were designed to have both cytotoxic and antiangiogenic effects. The antiangiogenic effect is mediated via inhibition of vascular endothelial growth factor -2 (VEGFR2). The cytotoxic effect is mediated by tubulin inhibition. For example, Compound 1 of Figure 1 overcomes two clinically important tumor resistance mechanisms that limit the activity of microtubule targeting agents: expression of P-glycoprotein and β III tubulin. Compound 1 of Figure 1 caused cellular microtubule depolymerization, arrested cells in the G₂/M phase and triggered apoptotic cell death. In vivo, this compound reduced tumor size and vascularity in two flank xenograft models [the BLBC MDA-MB-435 and U251 glioma models] and in a 4T1 triple negative breast orthotopic allograft model. In these *in vivo* models, the activity of Compound 1 of Figure 1 was superior to those of temozolomide (U251), docetaxel and sunitinib (MDA-MB-435 and 4T1) without overt toxicity to the animals.

The complexity of the angiogenic pathways implies that disrupting only a single aspect of angiogenesis may not result in significant clinical success. Multiple receptor tyrosine kinases (RTKs) are co-activated in tumors and redundant inputs drive and maintain downstream signaling, thereby limiting the efficacy of therapies targeting single RTKs. Resistance to VEGFR2 inhibition is associated with increased platelet-derived growth factor receptor- β (PDGFR β) expression in tumor endothelial cells, increased recruitment of pericytes to tumor vasculature, and increases in other proangiogenic factors. Similarly epidermal growth factor receptor (EGFR) inhibition can lead to VEGFR2 up-regulation which subsequently promotes tumor growth signaling independent of EGFR and thus contributes to the resistance of EGFR

inhibitors. The effect of EGFR inhibition can also be partially overcome by activation of PDGFR. Hence, targeting multiple RTKs maximizes the proportion of angiogenic signaling that is effectively targeted.

This invention discloses antiangiogenic agents which inhibit multiple RTKs such as VEGFR2, PDGFR β , and EGFR among several others. Hence, it was of interest to explore the effect of structural changes on activity against the RTKs VEGFR2, PDGFR β and EGFR in addition to having cytotoxic antitubulin effects with the goal of identifying single agents with antitubulin and multiple RTK inhibitory potential. Compounds 2-5 of Figure 1 of this invention were designed as conformationally restricted analogs of Compound 1 of Figure 1 of this invention.

Also identified as: Compound number, Figure 1:

RP/AG/159-306	2
RP/AG/159-313	3
RP/AG/159-321	4
RP/AG/159-341	5

Biological Evaluation

Antitubulin and RTK- inhibitory effects (Table 1)

Compounds 2, 4 and 5 of Figure 1 of this invention are effective and potent inhibitors of bovine tubulin assembly comparable with combretastatin A-4.

Compounds 2 - 5 of Figure 1 were evaluated for their activity against RTKs which are overexpressed by tumor endothelial cells. Compounds 2 - 5 of Figure 1 have potencies comparable with sunitinib and semaxinib against VEGFR2 (Table 1). Compounds 3-5 of Figure 1 have potencies comparable with erlotinib against EGFR. Compounds 3 and 4 of Figure 1 have potencies comparable with DMBI against PDGFR β .

Compounds 3-4 of Figure 1 show potent inhibition of A431 cells and show activity comparable to that of doxorubicin.

While paclitaxel and docetaxel are 3-fold less potent in β III-tubulin overexpressing cell line than in the wild type HeLa cells, compounds 2-5 of Figure 1 inhibited both cell lines with equal potency independent of overexpression of β III-tubulin.

Table 1. Inhibition of tubulin, colchicine binding and RTKs

Figure 1: compound	inhibition of			kinase inhibition IC ₅₀ [whole-cell assays]			A431 cytotoxicity	HeLa cytotoxicity	
	tubulin assembly IC ₅₀	colchicine binding		VEGFR2	PDGFR β	EGFR		Wild type	β III overexpressing
	(μ M)	(5 μ M inhibitor)	(1 μ M inhibitor)	(nM)	(nM)	(nM)	(nM)	(nM)	(nM)
2	3.3 $\pm$ 0.3			38.7 $\pm$ 7.1	90.3 $\pm$ 18.3	33.6 $\pm$ 5.6	40.1 $\pm$ 5.6	250 $\pm$ 0	250 $\pm$ 0
3	> 20 (no act)			26.7 $\pm$ 4.6	7.2 $\pm$ 0.9	2.6 $\pm$ 0.42	2.3 $\pm$ 0.3	5000 $\pm$ 0	5000 $\pm$ 0
4	0.48 $\pm$ 0.008	92 $\pm$ 0.2	73 $\pm$ 3	33.0 $\pm$ 5.0	10.3 $\pm$ 1.7	2.3 $\pm$ 0.3	1.2 $\pm$ 0.07	14 $\pm$ 2	14 $\pm$ 1
5	0.91 $\pm$ 0.03	72 $\pm$ 2		32.9 $\pm$ 4.9	30.2 $\pm$ 7.2	4.9 $\pm$ 0.6	8.1 $\pm$ 0.8	60 $\pm$ 0	58 $\pm$ 2
combretastatin A-4	1.2 $\pm$ 0.01	98 $\pm$ 0.3						1.8 $\pm$ 0.4	2.5 $\pm$ 0.7
paclitaxel								5.3 $\pm$ 2	16.1 $\pm$ 1
docetaxel								4.0 $\pm$ 2	13 $\pm$ 4
semaxinib				12.9					
sunitinib				18.9 $\pm$ 2.7	83.1 $\pm$ 10.1	172.1 $\pm$ 19.4			
erlotinib				124.7 $\pm$ 18.2	12.2 $\pm$ 1.9	1.2 $\pm$ 0.2			
DMBI					3.75				
doxorubicin							1.35 $\pm$ 0.03		

Effect on [³H]colchicine binding (Table 1)

Compounds 4 and 5 shown in Figure 1 were potent inhibitors (activity comparable with that of combretastatin A-4) of bovine brain tubulin assembly and of [³H]colchicine binding to tubulin, indicating that these compounds bind at the colchicine site on tubulin.

Table 2. Tumor cell inhibitory activity (NCI) GI₅₀ (10⁻⁸ M) of Compounds 2 and 4 of Figure 1

Panel/ Cell line	GI₅₀ (10⁻⁸ M)		Panel/ Cell line	GI₅₀ (10⁻⁸ M)		Panel/ Cell line	GI₅₀ (10⁻⁸ M)		Panel/ Cell line	GI₅₀ (10⁻⁸ M)	
Compound	2	4	Compound	2	4	Compound	2	4	Compound	2	4
Leukemia			Colon Cancer			Melanoma			Renal Cancer		
CCRF-CEM	22.6	3.35	COLO 205	23.2	2.63	LOX IMVI	52.1	5.88	786 - 0	93.4	9.32
HL-60(TB)	22.2	2.68	HCC-2998	31.8	7.11	MALME-3M	33.0	1.77	A498	19.7	2.02
K-562	11.1	3.37	HCT-116	36.8	3.50	M14	25.2	2.95	ACHN	83.0	17.2
MOLT-4	34.5	5.08	HCT-15	36.6	3.81	MDA-MB-435	34.1	2.14	CAKI-1	34.1	5.66
RPMI-8226	26.6	3.69	HT29		3.51	SK-MEL-2		2.86	RXF 393	21.2	2.54
SR	92.2	3.38	KM12	36.6	4.45	SK-MEL-28	36.8	4.87	SN12C	61.8	8.87
NSCLC			SW-	37.0	3.84	SK-MEL-5	32.5	5.42	TK10	12.3	

			620								
A549/ATCC	40.6	4.40	CNS Cancer			UACC- 257	10.8	7.82	UO-31	39.0	20.9
EKVX	46.3		SF-268	72.3	35.0	UACC-62	65.9	47.5	Prostate Cancer		
HOP-62	37.9	4.78	SF-295	19.2	3.04	Ovarian cancer			PC-3		4.96
HOP-92	18.9	4.71	SF-539	26.0	2.54	IGROVI	44.0	9.58	DU-145	38.3	4.44
NCI-H226	13.6	30.4	SNB- 19	54.9	5.47	OVCAR-3	28.5	3.52	Breast Cancer		
NCI-H23	32.0	4.58	SNB- 75	18.2	2.78	OVCAR-4	46.8		MCF7	24.8	3.33
NCI-H322M	36.2	7.36	U251	31.6	4.43	OVCAR-5	54.3	26.9	MDA- MB- 231/ATCC	64.1	6.37
NCI-H460	33.7	3.87				OVCAR-8	48.7	4.91	HS 578T	58.2	6.23
NCI-H522	31.6	2.39				NCI/ADR- RES	26.5	3.28	BT-549	75.5	4.82
						SK-OV-3	42.3	4.54	T-47D	12.8	
									MDA- MB-468	15.3	3.01

NCI 60 tumor panel (Table 2)

Compounds 2 (a tubulin and VEGFR2 inhibitor) and 4 (a tubulin, VEGFR2, EGFR and PDGFR β inhibitor) shown in Figure 1 were evaluated for tumor cytotoxicity in the NCI 60 tumor cell line panel. Both compounds show 2- to 3-digit nanomolar GI₅₀.

CAM Assay

Compound 4 shown in Figure 1 was tested for its effects on blood vessel formation in the chicken chorioallantoic membrane (CAM) antiangiogenic activity assay and was found to have an IC₅₀ value of $2.2 \pm 0.4 \mu\text{M}$ [sunitinib, IC₅₀ = $1.3 \pm 0.07 \mu\text{M}$; erlotinib IC₅₀ = $29.1 \pm 1.9 \mu\text{M}$]

In vivo studies

While not being bound to any particular theory on mechanism of action, we believe that Compound 4 shown in Figure 1 has four separate mechanisms of action in a single entity including inhibition of tubulin, PDGFR β , VEGFR2 and EGFR. Compound 4 shown in Figure 1 was evaluated in preclinical tumor models in mice.

4T1-Luc2GFP triple negative mouse breast cancer model

BALB/c mice were implanted with 7.5k 4T1-Luc2GFP triple negative mouse breast cancer cells orthotopically into mammary fat pad 4. 7 days after implantation, tumors are visible in over 90% of animals. At day 8 and continuing twice weekly until the experiment end, the MTD of compound 4·HCl (i.e. the hydrochloride salt of compound 4 shown in Figure 1), determined to be 40 mg/kg, was given IP to tumor-bearing mice; doxorubicin at its MTD of 1 mg/kg weekly was given as a comparison; Both drugs were in solvent (5% solutol-15, 5% PharmaSolve in normal saline) and a solvent control group was included in addition to sham

injected (untreated) group. Primary tumor volume and animal weights was assessed by calipers throughout the experiment.

Figure 2 shows the effect of Compound 4·HCl (HCl salt form of Compound 4 shown in Figure 1) on triple negative mouse breast tumors. In Figure 2, Compound 4·HCl (i.e. the salt form of Compound 4 shown in Figure 4, here as the hydrochloride salt form) significantly reduced 4T1 primary growth vs carrier or vs doxorubicin.

Figure 3 shows the effect of Compound 4 shown in Figure 1 (here as the HCl salt form) on animal weight. Doxorubicin began to result in weight loss in a few animals. However Compound 4·HCl resulted in no change in animal weight (animals gained weight, Figure 4), indicating lower systemic toxicity.


On day 40, all animals were injected IV with fluorescently labeled dextran as a marker of vasculature. Tumors were excised and weighed; lungs were excised and evaluated for metastases. Small micro metastases (1-9 cells without any vasculature); large micro metastases (>10 cells with no vasculature) and macrometastases (>10 cells with apparent vasculature) were counted. Figure 4 shows the effect of Compound 4 of Figure 4 (here as the HCl salt) on tumor weight.


Figure 4 shows the effect of the HCl salt form of Compound 4 of Figure 1 on animal weight. Compound 4·HCl reduced tumor weight at the end of the experiment.


Figure 5 shows the effect of Compound 4 of Figure 1 (here as the HCl salt form) on lung micro- and macrometastases. Compound 4·HCl reduced the number of lung small micro metastases and more importantly, in the 4·HCl compound treated animals none had any lung macrometastases.

In summary, we discovered that these conformationally restricted analogs of Compound 1 of Figure 1 had improved activities against PDGFR β and EGFR in addition to having tubulin and VEGFR2 inhibitory activities. We believe that in addition to delaying or preventing tumor cell resistance these water-soluble compounds with antiangiogenic effects via multiple RTK inhibition and cytotoxic effects via tubulin inhibition in single entities could perhaps circumvent pharmacokinetic problems of multiple agents, avoid drug-drug interactions, be used at lower doses to alleviate toxicity and be devoid of overlapping toxicities.

CHEMISTRY- SYNTHESIS SCHEME (GENERAL)



CHEMISTRY- SYNTHESIS SCHEMES



Experimental:

All evaporations were carried out in vacuum with a rotary evaporator. Analytical samples were dried in vacuo in a CHEM-DRY drying apparatus over P₂O₅ at 50 °C. Melting points were determined either using a MEL-TEMP II melting point apparatus with FLUKE 51 K/J electronic thermometer or using an MPA100 OptiMelt automated melting point system and are uncorrected. Nuclear magnetic resonance spectra for proton (¹H NMR) were recorded on the Bruker Avance II 400 (400 MHz) or Bruker Avance II 500 (500 MHz) NMR systems with TopSpin processing software. The chemical shift values (δ) are expressed in ppm (parts per million) relative to tetramethylsilane as an internal standard: s, singlet; d, doublet; dd, doublet of doublet; t, triplet; q, quartet; m, multiplet; br, broad singlet; td, triplet of doublet; dt, doublet of

triplet; quin, quintet. Thin-layer chromatography (TLC) was performed on Whatman® PE SIL G/UV254 flexible silica gel plates and the spots were visualized under 254 and 365 nm ultraviolet illumination. Proportions of solvents used for TLC are by volume. All analytical samples were homogeneous on TLC in at least two different solvent systems. Column chromatography was performed on the silica gel (70 to 230 meshes, Fisher Scientific) column. Flash chromatography was carried out on the CombiFlash® Rf systems, model COMBIFLASH RF. Pre-packed RediSep® Rf normal-phase flash columns (230 to 400 meshes) of various sizes were used. The amount (weight) of silica gel for column chromatography was in the range of 50-100 times the amount (weight) of the crude compounds being separated. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA. Element compositions are within $\pm$ 0.4% of the calculated values. Fractional moles of water or organic solvents frequently found in some analytical samples could not be prevented despite 24 to 48 hours of drying in vacuo and were confirmed where possible by their presence in the ^1H NMR spectra.

Methyl 3-amino-4-benzyl-1*H*-pyrrole-2-carboxylate (8)

Benzaldehyde (**6**, 20 g, 0.25 mol) and 3,3-dimethoxypropionitrile (35 g, 0.30 mol) were mixed together and added to a solution of sodium ethoxide in ethanol (0.5 M) during 15 min. The mixture was stirred at room temperature for 8 hours. Most of the solvent was removed in vacuo, and the residue was partitioned between EtOAc (500 mL) and water (450 mL). The organic layer was separated, washed with brine, dried with sodium sulphate and the solvent evaporated in vacuo. The residual oil was treated cautiously with 6 N HCl (75 mL), and the mixture was stirred at room temperature for 2 hours. The solid was filtered off, washed well with water, and dried in vacuo to give an off-white powder (**7**) which was shaken with methanol and 10% Pd/C under

50 psi H₂ in a hydrogenation bottle for 45 min. The catalyst was removed by filtration, a mixture of diethyl aminomalonate, sodium acetate, and water was added, and the mixture was stirred at room temperature for 8 hours. Most of the solvent was removed in vacuo, and the residue was partitioned between EtOAc and water. The organic layer was separated and dried over sodium sulphate and evaporated in vacuo. The residual yellow oil was dissolved in methanol containing sodium methoxide, stirred at room temperature for 3 hours and then heated to reflux for 30 minutes. Most of the solvent was evaporated in vacuo, and the residue was treated with water (200 mL) to give **8** as a light yellow solid which was flash chromatographed with 1% (v/v) CH₃OH in CHCl₃. mp: 120-122 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.62 (s, 2 H, CH₂) 3.68 (s, 3 H, CH₃) 4.84 (br, 2 H, exch, NH₂) 6.46 (d, *J* = 3.51 Hz, 1 H, 6-H) 7.11 - 7.16 (m, 1 H, C₆H₅) 7.19 - 7.27 (m, 4 H, C₆H₅) 10.47 (br, 1 H, exch, NH).

7-Benzyl-2-methyl-3*H*-pyrrolo[3,2-*d*]pyrimidin-4(5*H*)-one [9]

To a 250 mL flask was added **8** (1.5g, 6.51 mmol) and acetonitrile (30 mL). Dry HCl gas was bubbled through the solution at room temperature for 15 min. A precipitate was formed, and it dissolved as the reaction progressed. HCl gas was bubbled through the solution for an additional hour, and the mixture was stirred for 2 h. Most of the solvent was evaporated *in vacuo*, water (20 mL) was added, and the aqueous mixture was neutralized with ammonia to afford a precipitate that was removed by filtration, washed with water and dried in vacuo to afford a light yellow solid. Silica gel and methanol were added; the solvent was evaporated to afford a plug. The silica gel plug obtained was loaded onto a silica gel column and eluted with 1% (v/v) MeOH/CHCl₃. Fractions containing the product (TLC) were pooled, and the solvent was evaporated to afford **9** (1.12 g, 72%). TLC R_f = 0.42 (CH₃OH: CHCl₃; 1:20); white solid; mp,

254-256 °C; ¹H NMR, DMSO-d₆: δ 2.29 (s, 3 H, 2-CH₃) 3.90 (s, 2 H, CH₂) 7.07(d, *J* = 2.90 Hz, 1 H, Ar) 7.10 – 7.15, (m, 1 H, Ar) 7.21 – 7.24, (m, 4 H, Ar) 12.086 (s, 1H, exch, NH) Anal. Calcd. for C₁₄H₁₃N₃O . 0.1 H₂O: C, 69.75; H, 5.52; N, 17.43. Found C, 69.81; H, 5.52; N, 17.44.

7-Benzyl-4-chloro-2-methyl-5H-pyrrolo[3,2-*d*]pyrimidine [10]

Compound **9** (1.5 g, 6.27 mmol) was added to POCl₃ (12 mL) and heated at reflux for 3 h. The solvent was evaporated in vacuo, and the residue was adjusted to pH 8 with an ammonia solution. The resulting precipitate was removed by filtration, washed with water and dried in vacuo over P₂O₅ to afford a light yellow solid. Silica gel (4.5 g) and methanol (20 mL) were added; the solvent was evaporated to afford a plug. The silica gel plug obtained was loaded onto a silica gel column and eluted with 1% (v/v) CH₃OH /CHCl₃. Fractions containing the product (TLC) were pooled, and the solvent was evaporated to afford **10** (1.41 g, 87%). TLC R_f=0.56 (CH₃OH: CHCl₃; 1:20); white solid; mp 181-183 °C; ¹H NMR, DMSO-d₆: δ 2.61 (s, 3 H, 2-CH₃) 4.04 (s, 2 H, CH₂) 7.13 – 7.28 (m, 5 H, Ar) 7.68 (d, *J* = 2.72 Hz, 1 H, CH) 12.086 (s, 1H, exch, 5-NH) Anal. Calcd. for C₁₄H₁₂N₃Cl : C, 65.25; H, 4.69; N, 16.30. Found C, 65.23; H, 4.70; N, 16.31.

1-(7-Benzyl-2-methyl-5H-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (2)

Compound **10** (0.1 g, 0.38 mmol) and 6-methoxy-1,2,3,4-tetrahydroquinoline (0.07 g, 1.05 mmol) were dissolved in isopropanol (20 mL) and heated at reflux for 4 h. The solvent was evaporated in vacuo, and the residue was purified by column chromatography (CHCl₃: CH₃OH; 50:1; v/v) to give a brown solid (120.0 mg): yield = 80%; TLC R_f = 0.6 (CH₃OH: CHCl₃; 1:25).

pale yellow solid; mp 262-264 °C; ^1H NMR (400 MHz, DMSO- d_6) δ ppm 1.97 - 2.05 (m, 2 H, CH₂) 2.67 (s, 3 H, CH₃) 2.76 - 2.82 (m, 2 H, CH₂) 3.79 (s, 3 H, CH₃) 4.11 (s, 4 H, CH₂) 6.77 - 6.82 (m, 1 H, Ar) 6.92 - 6.96 (m, 1 H, Ar) 7.12 - 7.24 (m, 2 H, Ar) 7.28 - 7.34 (m, 4 H, Ar) 7.44 - 7.48 (m, 1 H, Ar) 10.88 (s, 1 H, exch, NH) 14.36 (s, 1 H, exch, HCl) Anal. Calcd. for C₂₄H₂₄N₄O·HCl·0.25H₂O: C, 67.75; H, 6.04; N, 13.17; Cl, 8.33. Found C, 67.84; H, 6.21; N, 12.95; Cl, 8.06.

7-Benzyl-4-chloro-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidine (11)

Compound **10** (300 mg, 1.16 mmol) was dissolved in dimethylformamide (20mL) and sodium hydride (31 mg, 1.28 mmol) was added under nitrogen. The mixture was allowed to stir for 15 minutes after no further production of hydrogen gas was observed. Methyl bromide (0.2 mL) was added and the reaction was stirred for 2 hours. The reaction was quenched by addition of water and ethylacetate was added. The organic layer was collected, washed with brine and dried over sodium sulphate. A silica gel plug was made and purified by column chromatography (CHCl₃:

MeOH; 100:1 v/v) to give an off-white solid yield = 83%; TLC R_f 0.5 (CH₃OH: CHCl₃; 1:25). white solid; mp, 145-147 °C ^1H NMR (400 MHz, DMSO- d_6) δ ppm 2.62 (s, 3 H, CH₃) 4.01 (s, 3 H, CH₃) 4.03 (s, 2 H, CH₂) 7.17 (td, J = 5.65, 2.76 Hz, 1 H, 6-CH) 7.26 - 7.30 (m, 4 H, C₆H₅) 7.64 (s, 1 H, C₆H₅).

7-Benzyl-*N*-(4-methoxyphenyl)-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine**(3)**

Compound **3** (synthesized from **11** and *p*-anisidine as described for **2**): yield = 79%; TLC R_f 0.5 (CH₃OH: CHCl₃; 1:20). white solid; mp, 291-292 °C; ¹H NMR (DMSO-*d*₆): δ 2.66 (s, 3 H, 2-CH₃) 3.6 (s, 3 H, NCH₃) 3.82 (s, 3 H, OCH₃) 4.08 (s, 2 H, CH₂) 7.08 (d, 2 H, *J* = 8.84 Hz, Ar) 7.17 – 7.26 (m, 6 H, Ar and 6-CH) 7.4 (d, 2 H, *J* = 8.73, Ar) 9.41 (br, 1H, exch, NH) 14.43 (s, 1H, exch, HCl). Anal. Calcd. for C₂₂H₂₂N₄O·HCl: C, 66.91; H, 5.87; N, 14.19; Cl, 8.98. Found C, 66.88; H, 5.86; N, 14.07; Cl, 8.84.

7-Benzyl-*N*-(4-methoxyphenyl)-*N*,2,5-trimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-amine (4)

Compound **4** (synthesized from **11** and 4-methoxy *N*-methyl aniline as described for **2**): yield = 74%; TLC R_f = 0.5 (CH₃OH: CHCl₃; 1:20). grey solid; mp, 186-187 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.73 (s, 3 H, CH₃) 2.80 (s, 3 H, CH₃) 3.63 (s, 3 H, CH₃) 3.78 (s, 3 H, CH₃) 4.08 (s, 2 H, CH₂) 7.00 (d, *J* = 9.03 Hz, 2 H, Ar) 7.22 (d, *J* = 5.52 Hz, 1 H, Ar) 7.25 - 7.33 (m, 6 H, Ar) 7.37 (s, 1 H, Ar) 8.33 (s, 1 H, Ar) 14.63 (s, 1 H, exch, HCl) Anal. Calcd. for C₂₃H₂₄N₄O·HCl: C, 67.55; H, 6.16; N, 13.70; Cl, 8.67. Found C, 67.41; H, 6.20; N, 13.59; Cl, 8.61.

1-(7-Benzyl-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline (5)

Compound **5** (synthesized from **11** and 6-methoxy-1,2,3,4-tetrahydroquinoline as described for **2**): yield = 76%; TLC R_f 0.6 (CH₃OH: CHCl₃; 1:20) white solid; mp, 130-132 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 2.07 (t, *J* = 6.53 Hz, 2 H, CH₂) 2.72 (s, 3 H, CH₃) 2.79 -


2.88 (m, 2 H, CH₂) 2.97 (s, 3 H, CH₃) 3.72 - 3.78 (m, 3 H, CH₃) 3.96 - 4.06 (m, 2 H, CH₂) 4.13 (s, 2 H, CH₂) 6.68 - 6.72 (m, 1 H, Ar) 6.79 (d, $J = 9.03$ Hz, 1 H, Ar) 6.91 (d, $J = 2.76$ Hz, 1 H, Ar) 7.22 (td, $J = 5.84, 2.64$ Hz, 1 H, Ar) 7.30 - 7.35 (m, 4 H, Ar) 7.50 (s, 1 H, Ar) 14.71 (s, 1 H, exch, HCl).

References:

1. Gangjee, A.; Pavana, R.K.; Ihnat, M.A.; Thorpe, J.E.; Disch, B.C.; Bastian, A.; Bailey-Downs, L.C.; Hamel, E.; Bai, R. Discovery of antitubulin agents with antiangiogenic activity as single entities with multitarget chemotherapy potential. *ACS. Med.Chem. Lett*, **2014**, doi: 10.1021/ml4004793
2. Gangjee, A.; Zaware, N.; Raghavan, S.; Disch, B. C.; Thorpe, J. E.; Bastian, A.; Ihnat, M. A. Synthesis and biological activity of 5-chloro-*N*4-substituted phenyl-9*H*-pyrimido[4,5-*b*]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents. *Bioorg. Med. Chem.* **2013**, *21*, 1857-1864.
3. Gangjee, A.; Kurup, S.; Ihnat, M.A.; Thorpe, J.E.; Disch, B.C. *N*^{*t*}-aryl-6-substituted-phenylmethyl-7*H*-pyrrolo[2,3-*d*]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors. *Bioorg. Med. Chem.* **2012**, *20*, 910-914.
4. Gangjee, A.; Zaware, N.; Raghavan, S.; Ihnat, M.; Shenoy, S.; Kisliuk, R. L. Single agents with designed combination chemotherapy potential: Synthesis and evaluation of substituted pyrimido[4,5-*b*]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents. *J. Med. Chem.* **2010**, *53*, 1563-1578.


What is claimed is:

1. A compound of the following formula, or a pharmaceutical salt, solvate, or hydrate of the compound of the following formula:





wherein R is selected from the group consisting of a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated.

2. A compound that is 7-Benzyl-4-chloro-2,5-dimethyl-5*H*-pyrrolo[3,2-*d*]pyrimidine, or a pharmaceutical salt, hydrate, or solvate of said compound.
3. A compound having the following formula, or a pharmaceutical salt, solvate, or hydrate of the compound having the following formula:




wherein R is selected from the group consisting of a straight or branched chain alkyl group having from 1 to 10 carbon atoms, wherein the alkyl group is partially or completely saturated, for use in treating cancer in a patient.

4. A compound, or a pharmaceutical salt, solvate, or hydrate of a compound, selected from the group consisting of 1-(7-Benzyl-2-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline and 1-(7-Benzyl-2,5-dimethyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)-6-methoxy-1,2,3,4-tetrahydroquinoline, for use in treating cancer.



R
3 H
4 CH₃



R
2 H
5 CH₃

Figure 1




Figure 2

animal weights




Figure 3

4T1 primary tumor weights




Figure 4

Lung (micro)met counts







Figure 5



R
3 H
4 CH₃



R
2 H
5 CH₃